CoChat
Sign Up
Cited by 62Immunodeficiency and Autoimmune DisordersT-cell and B-cell ImmunologyBlood disorders and treatments

The DOI matches its Crossref record; the references it cites are not checked yet.

Cytokines in Common Variable Immunodeficiency as Signs of Immune Dysregulation and Potential Therapeutic Targets – A Review of the Current Knowledge

Varzaneh, Farnaz Najmi, Keller, Bärbel, Unger, Susanne, Aghamohammadi, Asghar, Warnatz, Klaus, Rezaei, Nima·2014·Journal of Clinical Immunology
DOI 10.1007/s10875-014-0053-0
Open this paper in CoChat — free account

Abstract

Common variable immunodeficiency (CVID) is characterized by low levels of circulating immunoglobulins and compromised specific antibody response leading to frequent infections. Cytokines play an important role in the orchestration of the antibody response. Several previous studies have attempted to identify distinct cytokines responsible for the inflammatory changes and different manifestations of CVID, but there are conflicting results regarding the cytokine profiles in CVID patients. In light of this, an extensive review regarding the level of various cytokines and their potential therapeutic role in CVID patients was performed. This review delineates the contribution of interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-21, interferons, tumor necrosis factor (TNF)-α, IL-17, APRIL (a proliferation inducing ligand) and BAFF (B cell activating factor) in CVID disease and outline their potential therapeutic implications in these patients.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10875-014-0053-0

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In murine models, blocking or neutralizing IL-10 leads to increased levels of TNF and IL-6.

    “Experiments in murine models have shown that blocking or neutralizing IL-10 leads to increased levels of TNF and IL-6; on the contrary, exogenous IL-10 improves survival and reduces the levels of inflammatory cytokines (65).”

    From Macrophage Cytokines: Involvement in Immunity and Infectious Diseases (2014) · cites this paper as [65]

  • In murine models, exogenous IL-10 improves survival and reduces levels of inflammatory cytokines.

    “Experiments in murine models have shown that blocking or neutralizing IL-10 leads to increased levels of TNF and IL-6; on the contrary, exogenous IL-10 improves survival and reduces the levels of inflammatory cytokines (65).”

    From Macrophage Cytokines: Involvement in Immunity and Infectious Diseases (2014) · cites this paper as [65]

  • Reduced levels of IL-10 favor the development of gastrointestinal pathologies such as inflammatory bowel disease.

    “It has been observed that reduced levels of IL-10 favor the development of gastrointestinal pathologies such as inflammatory bowel disease (65).”

    From Macrophage Cytokines: Involvement in Immunity and Infectious Diseases (2014) · cites this paper as [65]

Citations

The citation lists haven’t been fetched yet

References 166 · Cited by 62

Research works printed but not linked: 160

  1. Cunningham-Rundles C, Kazbay K, Zhou Z, Mayer L. Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency. J Interferon Cytokine Res. 1995;15(3):269–76. · DOI
  2. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92 (1):34–48. Epub 1999/07/22. doi: 10.1006/clim.1999.4725 S1521-6616 (99) 94725-3 [pii]. PubMed PMID: 10413651. · DOI
  3. Cunningham-Rundles C. Common variable immunodeficiency. Curr Allergy Asthma Rep. 2001;1(5):421–9. Epub 2002/03/15. PubMed PMID: 11892068 · DOI
  4. Seppanen M, Aghamohammadi A, Rezaei N. Is there a need to redefine the diagnostic criteria for common variable immunodeficiency? Expert Rev Clin Immunol. 2014;10(1):1–5. doi: 10.1586/1744666X.2014.870478 . · DOI
  5. Saiki O, Ralph P, Cunningham-Rundles C, Good RA. Three distinct stages of B-cell defects in common varied immunodeficiency. Proc Natl Acad Sci U S A. 1982;79(19):6008–12. · DOI
  6. Cunningham-Rundles C, Radigan L, Knight AK, Zhang L, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. J Immunol. 2006;176(3):1978–87. · DOI
  7. Holm AM, Aukrust P, Aandahl EM, Muller F, Tasken K, Froland SS. Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency–involvement of protein kinase A type I. J Immunol. 2003;170(11):5772–7. · DOI
  8. Borte S, Pan-Hammarstrom Q, Liu C, Sack U, Borte M, Wagner U, et al. Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood. 2009;114(19):4089–98. doi: 10.1182/blood-2009-02-207423 . · DOI
  9. Di Renzo M, Serrano D, Zhou Z, George I, Becker K, Cunningham-Rundles C. Enhanced T cell apoptosis in common variable immunodeficiency: negative role of the fas/fasligand system and of the Bcl-2 family proteins and possible role of TNF-RS. Clin Exp Immunol. 2001;125 (1):117–22. Epub 2001/07/27. doi: cei1560 [pii]. PubMed PMID: 11472434; PubMed Central PMCID: PMC1906110. · DOI
  10. Fischer MB, Wolf HM, Hauber I, Eggenbauer H, Thon V, Sasgary M, et al. Activation via the antigen receptor is impaired in T cells, but not in B cells from patients with common variable immunodeficiency. Eur J Immunol. 1996;26(1):231–7. doi: 10.1002/eji.1830260136 . · DOI
  11. Fiedler W, Sykora KW, Welte K, Kolitz JE, Cunningham-Rundles C, Holloway K, et al. T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. Clin Immunol Immunopathol. 1987;44(2):206–18. · DOI
  12. Di Renzo M, Zhou Z, George I, Becker K, Cunningham-Rundles C. Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation. Clin Exp Immunol. 2000;120 (3):503–11. Epub 2000/06/09. doi: cei1239 [pii]. PubMed PMID: 10844530; PubMed Central PMCID: PMC1905559. · DOI
  13. North ME, Webster AD, Farrant J. Defects in proliferative responses of T cells from patients with common variable immunodeficiency on direct activation of protein kinase C. Clin Exp Immunol. 1991;85(2):198–201. · DOI
  14. North ME, Spickett GP, Allsop J, Webster AD, Farrant J. Defective DNA synthesis by T cells in acquired 'common-variable' hypogammaglobulinaemia on stimulation with mitogens. Clin Exp Immunol. 1989;76(1):19–23.
  15. Sneller MC, Strober W. Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency. J Immunol. 1990;144(10):3762–9. · DOI
  16. Aukrust P, Muller F, Froland SS. Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes. Clin Immunol Immunopathol. 1994;70 (3):217–24. Epub 1994/03/01. doi: S0090122984710324 [pii]. PubMed PMID: 7906214. · DOI
  17. Kruger G, Welte K, Ciobanu N, Cunningham-Rundles C, Ralph P, Venuta S, et al. Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol. 1984;4(4):295–303. · DOI
  18. Jaffe JS, Eisenstein E, Sneller MC, Strober W. T-cell abnormalities in common variable immunodeficiency. Pediatr Res. 1993;33 (1 Suppl):S24-7; discussion S7-8. Epub 1993/01/01. doi: 10.1203/00006450-199305001-00128 . PubMed PMID: 7679486. · DOI
  19. Stagg AJ, Funauchi M, Knight SC, Webster AD, Farrant J. Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 1994;96(1):48–53. · DOI
  20. Kondratenko I, Amlot PL, Webster AD, Farrant J. Lack of specific antibody response in common variable immunodeficiency (CVID) associated with failure in production of antigen-specific memory T cells. MRC Immunodeficiency Group. Clin Exp Immunol. 1997;108(1):9–13. Epub 1997/04/01. PubMed PMID: 9097904; PubMed Central PMCID: PMC1904616 · DOI
  21. Oliva A, Scala E, Quinti I, Paganelli R, Ansotegui IJ, Giovannetti A, et al. IL-10 production and CD40L expression in patients with common variable immunodeficiency. Scand J Immunol. 1997;46(1):86–90. · DOI
  22. Farrington M, Grosmaire LS, Nonoyama S, Fischer SH, Hollenbaugh D, Ledbetter JA, et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A. 1994;91(3):1099–103. · DOI
  23. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Galicier L, Lepelletier Y, Webster D, et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood. 2004;104 (8):2441–3. Epub 2004/07/01. doi: 10.1182/blood-2004-04-1325 2004-04-1325 [pii]. PubMed PMID: 15226176. · DOI
  24. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52. doi: 10.1038/32588 . · DOI
  25. McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005;79 (1):17–27. Epub 2004/12/15. doi: 79/1/17 [pii] 10.1128/JVI.79.1.17-27.2005 . PubMed PMID: 15596797; PubMed Central PMCID: PMC538703. · DOI
  26. Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J, et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 2004;103 (4):1391–7. Epub 2003/10/11. doi: 10.1182/blood-2003-06-1959 2003-06-1959 [pii]. PubMed PMID: 14551144. · DOI
  27. Rogge L. A genomic view of helper T cell subsets. Ann N Y Acad Sci. 2002;975:57–67. · DOI
  28. Rezaei N, Aghamohammadi A, Kardar GA, Nourizadeh M, Pourpak Z. T- helper 1 and 2 cytokine assay in patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 2008;18(6):449–53.
  29. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol. 2004;114 (6):1265–73; quiz 74. Epub 2004/12/04. doi: S0091674904026429 [pii] 10.1016/j.jaci.2004.10.019 . PubMed PMID: 15577820. · DOI
  30. Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev. 2013;252(1):104–15. doi: 10.1111/imr.12028 . · DOI
  31. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med. 2012;209(7):1241–53. doi: 10.1084/jem.20120994 . · DOI
  32. Rezaei N, Aghamohammadi A, Shakiba Y, Mahmoudi M, Jalali A, Moradi B, et al. Cytokine gene polymorphisms in common variable immunodeficiency. Int Arch Allergy Immunol. 2009;150 (1):1–7. Epub 2009/04/03. doi: 000210374 [pii] 10.1159/000210374 . PubMed PMID: 19339796. · DOI
  33. Ishida H. [Clinical implication of IL-10 in patients with immune and inflammatory diseases]. Rinsho Byori. 1994;42 (8):843–52. Epub 1994/08/01. PubMed PMID: 7933621.
  34. Briere F, Bridon JM, Chevet D, Souillet G, Bienvenu F, Guret C, et al. Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. J Clin Invest. 1994;94(1):97–104. doi: 10.1172/JCI117354 . · DOI
  35. Zielen S, Bauscher P, Hofmann D, Meuer SC. Interleukin 10 and immune restoration in common variable immunodeficiency. Lancet. 1993;342 (8873):750–1. Epub 1993/09/18. doi: 0140-6736 (93) 91746-9 [pii]. PubMed PMID: 8103865.
  36. Pastorelli G, Roncarolo MG, Touraine JL, Peronne G, Tovo PA, de Vries JE. Peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) produce reduced levels of interleukin-4, interleukin-2 and interferon-gamma, but proliferate normally upon activation by mitogens. Clin Exp Immunol. 1989;78(3):334–40.
  37. Ferrer JM, Iglesias J, Hernandez M, Matamoros N. Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients. Clin Exp Immunol. 1995;102(2):286–9. · DOI
  38. Fischer MB, Hauber I, Vogel E, Wolf HM, Mannhalter JW, Eibl MM. Defective interleukin-2 and interferon-gamma gene expression in response to antigen in a subgroup of patients with common variable immunodeficiency. The Journal of allergy and clinical immunology. 1993;92(2):340–52. PubMed PMID: 8349943 · DOI
  39. Eisenstein EM, Jaffe JS, Strober W. Reduced interleukin-2 (IL-2) production in common variable immunodeficiency is due to a primary abnormality of CD4+ T cell differentiation. J Clin Immunol. 1993;13(4):247–58. · DOI
  40. Ibanez C, Sune P, Fierro A, Rodriguez S, Lopez M, Alvarez A, et al. Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia. BioDrugs. 2005;19(1):59–65. · DOI
  41. Bankers-Fulbright JL, Kalli KR, McKean DJ. Interleukin-1 signal transduction. Life Sci. 1996;59(2):61–83. · DOI
  42. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32. doi: 10.1182/blood-2010-07-273417 . · DOI · Paper page
  43. Rezaei N, Amirzargar AA, Shakiba Y, Mahmoudi M, Moradi B, Aghamohammadi A. Proinflammatory cytokine gene single nucleotide polymorphisms in common variable immunodeficiency. Clin Exp Immunol. 2009;155 (1):21–7. Epub 2008/12/17. doi: CEI3790 [pii] 10.1111/j.1365-2249.2008.03790.x . PubMed PMID: 19076825; PubMed Central PMCID: PMC2665675. · DOI
  44. Zielen S, Dengler TJ, Bauscher P, Meuer SC. Defective CD2 T cell pathway activation in common variable immunodeficiency (CVID). Clin Exp Immunol. 1994;96(2):253–9. · DOI
  45. Trujillo CM, Muskus C, Arango J, Patino PJ, Montoya CJ. Quantitative and functional evaluation of innate immune responses in patients with common variable immunodeficiency. Journal of investigational allergology & clinical immunology. 2011;21(3):207–15. PubMed PMID: 21548449
  46. Haveman LM, Scherrenburg J, Maarschalk-Ellerbroek LJ, Hoek PD, Schuurman R, de Jager W, et al. T-cell response to viral antigens in adults and children with common variable immunodeficiency and specific antibody deficiency. Clin Exp Immunol. 2010;161(1):108–17. doi: 10.1111/j.1365-2249.2010.04159.x . · DOI
  47. Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240(4856):1169–76. · DOI
  48. Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett. 2007;114(1):1–8. doi: 10.1016/j.imlet.2007.08.005 . · DOI
  49. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5 (179):179ra43. doi: 10.1126/scitranslmed.3005265 . PubMed PMID: 23552371; PubMed Central PMCID: PMC3686517. · DOI
  50. Isgro A, Marziali M, Mezzaroma I, Luzi G, Mazzone AM, Guazzi V, et al. Bone marrow clonogenic capability, cytokine production, and thymic output in patients with common variable immunodeficiency. J Immunol. 2005;174(8):5074–81. · DOI
  51. Inoue Y, Kondo N, Motoyoshi F, Inoue R, Orii T. Interleukin-2 and interferon-gamma production by peripheral blood lymphocytes of patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 1994;4(3):122–5.
  52. Giovannetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, Mileo AM, et al. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol. 2007;178(6):3932–43. · DOI
  53. Agarwal S, Smereka P, Harpaz N, Cunningham-Rundles C, Mayer L. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis. 2011;17(1):251–9. doi: 10.1002/ibd.21376 . · DOI
  54. Pons J, Ferrer JM, Martinez-Pomar N, Iglesias-Alzueta J, Matamoros N. Costimulatory molecules and cytokine production by T lymphocytes in common variable immunodeficiency disease. Scand J Immunol. 2006;63(5):383–9. doi: 10.1111/j.1365-3083.2006.01753.x . · DOI
  55. Cunningham-Rundles C, Kazbay K, Hassett J, Zhou Z, Mayer L. Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethylene glycol-conjugated interleukin-2. N Engl J Med. 1994;331(14):918–21. doi: 10.1056/NEJM199410063311405 . · DOI
  56. Cunningham-Rundles C, Mayer L, Sapira E, Mendelsohn L. Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2. Clin Immunol Immunopathol. 1992;64(1):46–56. · DOI
  57. Cunningham-Rundles C, Bodian C, Ochs HD, Martin S, Reiter-Wong M, Zhuo Z. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol. 2001;100(2):181–90. doi: 10.1006/clim.2001.5052 . · DOI
  58. Rump JA, Jahreis A, Schlesier M, Stecher S, Peter HH. A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 1997;110(2):167–73. PubMed Central PMCID: PMC2265503. · DOI
  59. Bergstedt-Lindqvist S, Moon HB, Persson U, Moller G, Heusser C, Severinson E. Interleukin 4 instructs uncommitted B lymphocytes to switch to IgG1 and IgE. Eur J Immunol. 1988;18(7):1073–7. doi: 10.1002/eji.1830180716 . · DOI
  60. Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2):66–70. · DOI
  61. Rezaei N, Haji-Molla-Hoseini M, Aghamohammadi A, Pourfathollah AA, Moghtadaie M, Pourpak Z. Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. J Clin Immunol. 2008;28(1):78–84. doi: 10.1007/s10875-007-9135-6 . · DOI
  62. Thon V, Wolf HM, Sasgary M, Litzman J, Samstag A, Hauber I, et al. Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients. Clin Exp Immunol. 1997;110(2):174–81. · DOI
  63. Kokron CM, Errante PR, Barros MT, Baracho GV, Camargo MM, Kalil J, et al. Clinical and laboratory aspects of common variable immunodeficiency. An Acad Bras Cienc. 2004;76 (4):707–26. Epub 2004/11/24. doi: S0001-37652004000400007 [pii]/S0001-37652004000400007. PubMed PMID: 15558152. · DOI
  64. Agondi RC, Barros MT, Rizzo LV, Kalil J, Giavina-Bianchi P. Allergic asthma in patients with common variable immunodeficiency. Allergy. 2010;65(4):510–5. doi: 10.1111/j.1398-9995.2009.02211.x . · DOI
  65. Agondi RC, Barros MT, Kokron CM, Cohon A, Oliveira AK, Kalil J, et al. Can patients with common variable immunodeficiency have allergic rhinitis? American journal of rhinology & allergy. 2013;27(2):79–83. doi: 10.2500/ajra.2013.27.3855. PubMed PMID: 2356219 · DOI
  66. Borte S, Lanig H, Borte M, Fasshauer M, Sack U. Therapeutic implications of the IL-21: IL-4 receptor system in children with common variable immunodeficiency syndrome. Klin Padiatr. 2010;222(6):362–7. doi: 10.1055/s-0030-1265207 . · DOI
  67. Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AE, Graber P, et al. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 1993;363(6425):172–6. · DOI
  68. Del Vecchio GC, Martire B, Lassandro G, Cecinati V, De Mattia D, Ciccarelli M, et al. Reduced interleukin-5 production by peripheral CD4+ T cells in common variable immunodeficiency patients. Immunopharmacol Immunotoxicol. 2008;30(4):679–86. doi: 10.1080/08923970802278102 . · DOI
  69. Smith CI, Moller G, Severinson E, Hammarstrom L. Frequencies of interleukin-5 mRNA-producing cells in healthy individuals and in immunoglobulin-deficient patients, measured by in situ hybridization. Clin Exp Immunol. 1990;81(3):417–22. · DOI
  70. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101(2):311–20. doi: 10.1172/JCI1368 . · DOI
  71. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–88. doi: 10.1016/j.bbamcr.2011.01.034 . · DOI · Paper page
  72. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5. doi: 10.1002/eji.201040391 . · DOI
  73. Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse 3rd HC, Goldschmidt H, et al. IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood. 2010;115(9):1746–54. doi: 10.1182/blood-2009-08-237941 . · DOI
  74. Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994;53(8):521–4. · DOI
  75. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991;147(1):117–23. Epub 1991/07/01. PubMed PMID: 2051017 · DOI
  76. Ishihara K, T H. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13 ((4–5)):357–68. · DOI · Paper page
  77. T H. Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86 (7):717–30. · DOI · Paper page
  78. Ueland T, Froland SS, Bollerslev J, Aukrust P. Increased levels of biochemical markers of bone turnover in relation to persistent immune activation in common variable immunodeficiency. Eur J Clin Investig. 2001;31(1):72–8. PubMed PMID: 11168441. · DOI
  79. Hong R, Agrawal S, Gollapudi S, Gupta S. Impaired pneumovax-23-induced monocyte-derived cytokine production in patients with common variable immunodeficiency. J Clin Immunol. 2010;30(3):435–41. doi: 10.1007/s10875-010-9371-z . · DOI
  80. Pandolfi F, Paganelli R, Cafaro A, Oliva A, Giovannetti A, Scala E, et al. Abnormalities of lymphocyte subpopulations in CVI do not correlate with increased production of IL-6. Immunodeficiency. 1993;4(1–4):19–23.
  81. vd Heyden-Rynsch BF, Diener C, Vogelsang H, Jager L. [In vitro IL-6- and immunoglobulin-production in patients with variable immunodeficiency syndrome (CVID)]. Immunitat und Infektion. 1993;21 Suppl 1:43–4. PubMed PMID: 8344691.
  82. van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(2):113–9. · DOI
  83. Kikuchi K, Kasai H, Watanabe A, Lai AY, Kondo M. IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression. J Immunol. 2008;181(1):383–92. · DOI
  84. Dias S, Silva Jr H, Cumano A, Vieira P. Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. J Exp Med. 2005;201(6):971–9. doi: 10.1084/jem.20042393 . · DOI
  85. Appasamy PM. Interleukin-7 and lymphopoiesis: biological and clinical implications. Cancer Treat Res. 1995;80:235–60. · DOI
  86. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. The Journal of experimental medicine. 1994;180(5):1955–60. PubMed PMID: 7964471; PubMed Central PMCID: PMC2191751 · DOI
  87. Johnson SE, Shah N, Panoskaltsis-Mortari A, LeBien TW. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. J Immunol. 2005;175(11):7325–31. · DOI
  88. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7(1):73–9. doi: 10.1038/83381 . · DOI
  89. Ponchel F, Cuthbert RJ, Goeb V. IL-7 and lymphopenia. Clin Chim Acta. 2011;412 (1–2):7–16. Epub 2010/09/21. doi: S0009-8981 (10) 00568-1 [pii] 10.1016/j.cca.2010.09.002 . PubMed PMID: 20850425. · DOI
  90. Davis CC, Marti LC, Sempowski GD, Jeyaraj DA, Szabolcs P. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Res. 2010;70 (13):5249–58. Epub 2010/06/10. doi: 0008–5472. CAN-09-2860 [pii] 10.1158/0008-5472.CAN-09-2860 . PubMed PMID: 20530666; PubMed Central PMCID: PMC2896454. · DOI
  91. Holm AM, Aukrust P, Damas JK, Muller F, Halvorsen B, Froland SS. Abnormal interleukin-7 function in common variable immunodeficiency. Blood. 2005;105 (7):2887–90. Epub 2004/12/16. doi: 2004-06-2423 [pii] 10.1182/blood-2004-06-2423 . PubMed PMID: 15598813. · DOI
  92. Tang J, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Ryan DH. TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J Immunol. 1997;159(1):117–25. · DOI
  93. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929–79. doi: 10.1146/annurev.immunol.22.012703.104622 . · DOI
  94. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89(5):1890–3. · DOI · Paper page
  95. Fevang B, Yndestad A, Sandberg WJ, Holm AM, Muller F, Aukrust P, et al. Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol. 2007;147(3):521–5. doi: 10.1111/j.1365-2249.2006.03314.x . · DOI
  96. Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143(2):347–55. doi: 10.1053/j.gastro.2012.04.045 . · DOI
  97. Zhou Z, Huang R, Danon M, Mayer L, Cunningham-Rundles C. IL-10 production in common variable immunodeficiency. Clin Immunol Immunopathol. 1998;86 (3):298–304. Epub 1998/04/29. doi: S0090122997944834 [pii]. PubMed PMID: 9557163. · DOI
  98. Kasztalska K, Ciebiada M, Cebula-Obrzut B, Gorski P. Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study. Clinical drug investigation. 2011;31(5):299–307. doi: 10.2165/11586710-000000000-00000. PubMed PMID: 21473654 · DOI
  99. Rezaei N, Aghamohammadi A, Mahmoudi M, Shakiba Y, Kardar GA, Mahmoudi M, et al. Association of IL-4 and IL-10 gene promoter polymorphisms with common variable immunodeficiency. Immunobiology. 2010;215(1):81–7. doi: 10.1016/j.imbio.2009.01.011 . · DOI
  100. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547–9. · DOI · Paper page
  101. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med. 1995;181(2):817–21. · DOI
  102. Smith T, Hewson AK, Kingsley CI, Leonard JP, Cuzner ML. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol. 1997;150(6):1909–17.
  103. Cambronero R, Sewell WA, North ME, Webster AD, Farrant J. Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency. J Immunol. 2000;164(1):488–94. · DOI
  104. Martinez-Pomar N, Raga S, Ferrer J, Pons J, Munoz-Saa I, Julia MR, et al. Elevated serum interleukin (IL)-12p40 levels in common variable immunodeficiency disease and decreased peripheral blood dendritic cells: analysis of IL-12p40 and interferon-gamma gene. Clin Exp Immunol. 2006;144(2):233–8. doi: 10.1111/j.1365-2249.2006.03063.x . · DOI
  105. McQuaid A, Tormey VJ, Trafford B, Webster AD, Bofill M. Evidence for increased expression of regulatory cytokine receptors interleukin-12R and interleukin-18R in common variable immunodeficiency. Clin Exp Immunol. 2003;134(2):321–7. · DOI
  106. Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs. 2007;10(1):53–9. Epub 2006/12/26. PubMed PMID: 17187316
  107. Cunningham-Rundles C, Radigan L. Deficient IL-12 and dendritic cell function in common variable immune deficiency. Clin Immunol. 2005;115 (2):147–53. Epub 2005/05/12. doi: S1521-6616 (04) 00373-0 [pii] 10.1016/j.clim.2004.12.007 . PubMed PMID: 15885637. · DOI
  108. Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med. 2002;196(7):969–77. · DOI
  109. Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007;282 (48):34605–10. Epub 2007/09/22. doi: M705100200 [pii] 10.1074/jbc.M705100200 . PubMed PMID: 17884812; PubMed Central PMCID: PMC2323680. · DOI
  110. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57–63. doi: 10.1038/35040504 . · DOI
  111. Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol. 2007;179 (9):5886–96. Epub 2007/10/20. doi: 179/9/5886 [pii]. PubMed PMID: 17947662. · DOI
  112. Kotlarz D, Zietara N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J, et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med. 2013;210(3):433–43. doi: 10.1084/jem.20111229 . · DOI
  113. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. The Journal of biological chemistry. 2007;282(28):20053–7. doi: 10.1074/jbc.R700006200. PubMed PMID: 17502368 · DOI
  114. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001;69(6):912–20. · DOI
  115. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84. doi: 10.1038/ni.1863 . · DOI · Paper page
  116. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. The Journal of general virology. 2000;81(Pt 10):2341–64. PubMed PMID: 10993923 · DOI
  117. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4):461–70. · DOI
  118. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010;6(1):40–9. doi: 10.1038/nrrheum.2009.237 . · DOI
  119. Strannegard O, Bjorkander J, Hellstrand K, Pacsa A, Hermodsson S, Hanson LA. Interferon and beta 2-microglobulin in patients with common variable immunodeficiency or selective IgA deficiency. International archives of allergy and applied immunology. 1987;84(3):217–22. PubMed PMID: 2443457 · DOI
  120. Yu JE, Knight AK, Radigan L, Marron TU, Zhang L, Sanchez-Ramon S, et al. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. The Journal of allergy and clinical immunology. 2009;124 (2):349–56, 56 e1-3. doi: 10.1016/j.jaci.2009.05.019 . PubMed PMID: 19592080; PubMed Central PMCID: PMC2908501. · DOI
  121. Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature. 1982;298(5877):859–63. · DOI
  122. Hauber I, Fischer MB, Eibl MM. Patients with common variable immunodeficiency (CVID) display aberrant IL-2 and IFN-gamma mRNA levels. Immunodeficiency. 1993;4(1–4):25–9.
  123. Serrano D, Becker K, Cunningham-Rundles C, Mayer L. Characterization of the T cell receptor repertoire in patients with common variable immunodeficiency: oligoclonal expansion of CD8 (+) T cells. Clin Immunol. 2000;97(3):248–58. doi: 10.1006/clim.2000.4941 . · DOI
  124. North ME, Ivory K, Funauchi M, Webster AD, Lane AC, Farrant J. Intracellular cytokine production by human CD4+ and CD8+ T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry. Clin Exp Immunol. 1996;105(3):517–22. · DOI
  125. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163–96. Epub 2001/03/13. doi: 19/1/163 [pii] 10.1146/annurev.immunol.19.1.163 . PubMed PMID: 11244034. · DOI
  126. Berry M, Brightling C, Pavord I, Wardlaw A. TNF-alpha in asthma. Curr Opin Pharmacol. 2007;7 (3):279–82. Epub 2007/05/04. doi: S1471-4892 (07) 00063-X [pii] 10.1016/j.coph.2007.03.001 . PubMed PMID: 17475560. · DOI
  127. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68 (10):930–41. Epub 2010/08/10. doi: S0006-3223 (10) 00601-3 [pii] 10.1016/j.biopsych.2010.06.012 . PubMed PMID: 20692646. · DOI · Paper page
  128. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67 (5):446–57. Epub 2009/12/18. doi: S0006-3223 (09) 01229-3 [pii] 10.1016/j.biopsych.2009.09.033 . PubMed PMID: 20015486. · DOI · Paper page
  129. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut. 2002;51(1):37–43. · DOI
  130. Chatzantoni K, Mouzaki A. Anti-TNF-alpha antibody therapies in autoimmune diseases. Curr Top Med Chem. 2006;6(16):1707–14. · DOI
  131. Cazzola M, Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol. 2006;6 (1):43–50. Epub 2006/03/01. doi: 10.1097/01.all.0000199798.10047.74 00130832-200602000-00009 [pii]. PubMed PMID: 16505611. · DOI
  132. Aukrust P, Lien E, Kristoffersen AK, Muller F, Haug CJ, Espevik T, et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency–possible immunologic and clinical consequences. Blood. 1996;87(2):674–81. · DOI
  133. Chua I, Standish R, Lear S, Harbord M, Eren E, Raeiszadeh M, et al. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 2007;150 (2):306–11. Epub 2007/09/08. doi: CEI3481 [pii] 10.1111/j.1365-2249.2007.03481.x . PubMed PMID: 17822445; PubMed Central PMCID: PMC2219360. · DOI
  134. Hatab AZ, Ballas ZK. Caseating granulomatous disease in common variable immunodeficiency treated with infliximab. The Journal of allergy and clinical immunology. 2005;116(5):1161–2. doi: 10.1016/j.jaci.2005.08.041. PubMed PMID: 16275393 · DOI
  135. Thatayatikom A, Thatayatikom S, White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005;95 (3):293–300. Epub 2005/10/05. doi: S1081-1206 (10) 61228-8 [pii] 10.1016/S1081-1206(10)61228-8 . PubMed PMID: 16200822. · DOI
  136. Barbosa RR, Silva SP, Silva SL, Melo AC, Pedro E, Barbosa MP, et al. Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One. 2011;6(8):e22848. doi: 10.1371/journal.pone.0022848 . · DOI
  137. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–67. doi: 10.1016/j.immuni.2008.03.004 . · DOI
  138. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6 (2):R120-8. Epub 2004/04/03. doi: 10.1186/ar1038 ar1038 [pii]. PubMed PMID: 15059275; PubMed Central PMCID: PMC400429. · DOI
  139. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218–22. doi: 10.1172/JCI28508 . · DOI
  140. Mannon PJ, Fuss IJ, Dill S, Friend J, Groden C, Hornung R, et al. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology. 2006;131 (3):748–56. Epub 2006/09/06. doi: S0016-5085 (06) 01311-4 [pii] 10.1053/j.gastro.2006.06.022 . PubMed PMID: 16952544. · DOI
  141. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24(3):203–15. doi: 10.1016/j.cytogfr.2013.04.003 . · DOI
  142. Salzer U, Chapel HM, Webster AD, Pan-Hammarstrom Q, Schmitt-Graeff A, Schlesier M, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37(8):820–8. doi: 10.1038/ng1600 . · DOI
  143. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–56. · DOI
  144. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465–75. doi: 10.1038/nri844 . · DOI
  145. Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol. 2005;174(9):5537–44. · DOI
  146. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005;115(11):3083–92. doi: 10.1172/JCI25265 . · DOI
  147. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006;54(1):192–201. doi: 10.1002/art.21526 . · DOI
  148. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15(9):570–6. · DOI
  149. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37(8):829–34. doi: 10.1038/ng1601 . · DOI
  150. Losi CG, Salzer U, Gatta R, Lougaris V, Cattaneo G, Meini A, et al. Mutational analysis of human BLyS in patients with common variable immunodeficiency. J Clin Immunol. 2006;26(4):396–9. doi: 10.1007/s10875-006-9026-2 . · DOI
  151. Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol. 2007;124(2):182–9. doi: 10.1016/j.clim.2007.04.012 . · DOI
  152. Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, et al. Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency. International journal of molecular medicine. 2008;21(2):233–8. PubMed PMID: 18204790 · DOI
  153. Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2012;188(1):497–503. doi: 10.4049/jimmunol.1102321 . · DOI
  154. Fischer MB, Hauber I, Eggenbauer H, Thon V, Vogel E, Schaffer E, et al. A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency. Blood. 1994;84(12):4234–41. · DOI
  155. Koval'chuk LV, Khoreva MV, Varivoda AS, Pashchenko OE, Gracheva LA, Bykova LP, et al. Analysis of toll-like receptor-dependent production of proinflammatory cytokines in vitro by human peripheral blood mononuclears of donors and patients with primary immunodeficiency. Bull Exp Biol Med. 2007;144(1):63–5. PubMed PMID: 18256754. · DOI
  156. Pandolfi F, Paganelli R, Oliva A, Quinti I, Polidori V, Fanales-Belasio E, et al. Increased IL-6 gene expression and production in patients with common variable immunodeficiency. Clin Exp Immunol. 1993;92(2):239–44. · DOI
  157. Junker U, vd Heyden-Rynsch B, Diener C, Vogelsang H, Jager L. In patients with common variable immunodeficiency, interleukin-6 and expression of its receptor on B-cells are normal. Cell Biol Int. 1993;17 (6):609–14. Epub 1993/06/01. doi: S1065699583711066 [pii]. PubMed PMID: 8348119. · DOI
  158. Rezaei N, Aghamohammadi A, Nourizadeh M, Kardar GA, Pourpak Z, Zare A, et al. Cytokine production by activated T cells in common variable immunodeficiency. Journal of investigational allergology & clinical immunology. 2010;20(3):244–51. PubMed PMID: 20635790
  159. Pastorelli G, Roncarolo MG, Touraine JL, Rousset F, Pene J, de Vries JE. Interleukin-4 suppresses immunoglobulin production by peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) induced by supernatants of T cell clones. Clin Exp Immunol. 1989;78(3):341–7.
  160. Clemente A, Pons J, Lanio N, Matamoros N, Ferrer JM. CD27 (+) B cells from a subgroup of common variable immunodeficiency patients are less sensitive to apoptosis rescue regardless of interleukin-21 signalling. Clin Exp Immunol. 2013;174(1):97–108. doi: 10.1111/cei.12150 . · DOI

Metadata

Authors
Varzaneh, F. N., Keller, B., Unger, S., Aghamohammadi, A., Warnatz, K., & Rezaei, N.
Affiliations
  • Children's Medical Center (IR)
  • University of Freiburg (DE)
Corresponding author
Rezaei, Nima
ORCID
Venue
Journal of Clinical Immunology
Publisher
Springer Science and Business Media LLC
Published
2014-05-15
Volume
34
Issue
5
Pages
524-543
ISSN
  • 0271-9142 (ISSN-L)
  • 1573-2592
DOI
10.1007/s10875-014-0053-0
OpenAlex
W1993207349
Cited by
62
References
166
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 12 · 2015: 6 · 2014: 5
FWCI
0.91
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Clinical Immunology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bundesministerium für Bildung und Forschung
  • Tehran University of Medical Sciences and Health Services
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Hematology › Blood disorders and treatments
Keywords
common variable immunodeficiency, cytokines, immune dysregulation, antibody response, interleukins, interferon, TNF-α, IL-17, APRIL, BAFF, therapeutic target, inflammation
MeSH terms
Antibody Formation, B-Lymphocytes, Gene Expression Regulation, Humans, Immunoglobulins, Lymphocyte Activation, Polymorphism, Genetic, T-Lymphocytes, Signal Transduction, Cytokines, Common Variable Immunodeficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review